Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer

There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]

read more
Showing the single result
  TOP